TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05029635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
Study: NCT05248386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study: NCT05056727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.
Study: NCT05972655
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study: NCT06408688
Drug: Immune checkpoint inhibitors plus Iscador® Qu.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
Study: NCT05869383
Drug: Ophiochepalus striatus extract
Normalized name: Bletilla striata bulb extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophiochepalus striatus extract 2x5 grams
Study: NCT05869383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2x5 grams
Study: NCT05587478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-323, oral administration
Study: NCT06541535
Drug: Fluid resuscitation with Ringer Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Study: NCT05658874
Drug: Bladder Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
Study: NCT06071936
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06071936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05253105
Drug: TAB006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
Study: NCT05466448
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
Study: NCT06255210
Drug: Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
Study: NCT05692856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
Study: NCT04601857
Drug: futibatinib and pembrolizumab (KEYTRUDA®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
Study: NCT05474378
Drug: B7-H3CART
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12.
Study: NCT06134271
Drug: Continue previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue using the previous treatment regimen for treatment.
Study: NCT05262959
Drug: Donafenib, PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
Study: NCT05256745
Drug: TTP488
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
Study: NCT05256745
Drug: TC
Normalized name: PTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
Study: NCT05256745
Drug: Chemotherapy regimen that includes ddAC
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
Study: NCT06029296
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg
Study: NCT06029296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT05759754
Drug: TCM+ Routine Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued.
Study: NCT05759754
Drug: Routine Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
Study: NCT05184478
Drug: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached.
Study: NCT05184478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase.
Study: NCT06705062
Drug: Standard dose PTCY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
Study: NCT05277922
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Study: NCT06238817
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT05728944
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary vehicle ophthalmic solution
Study: NCT06287606
Drug: CTP0302-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
Study: NCT06287606
Drug: CTP0302-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
Study: NCT05627557
Drug: Acetaminophen/ Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
Study: NCT05035485
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Study: NCT06105918
Drug: Lutetium Lu 177 PSMA-10.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05019521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT05869474
Drug: Gem/nab-P Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
Study: NCT05355766
Drug: CN128 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelator, oral tablets
Study: NCT05521269
Drug: ANX1502
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANX1502 is a prodrug of ANX1439.
Study: NCT05521269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT06254950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 placebo-matching capsules.
Study: NCT05880849
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
Study: NCT06074497
Drug: KGX101- Cohort -1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
Study: NCT06074497
Drug: KGX101- Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
Study: NCT06074497
Drug: KGX101- Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
Study: NCT06074497
Drug: KGX101- Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
Study: NCT06074497
Drug: KGX101- Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
Study: NCT06074497
Drug: KGX101- Cohort 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
Study: NCT05482893
Drug: KEYTRUDA® (pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D: Cohort 3, 4, and 5.
Study: NCT05482893
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Study: NCT05482893
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Study: NCT05482893
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Study: NCT05482893
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort 2b
Study: NCT06234514
Drug: Jueling Mingmu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
Study: NCT06072586
Drug: BDTX-1535
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDTX-1535 is an inhibitor of EGFR mutations
Study: NCT04620759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
Study: NCT04821817
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
Study: NCT06165367
Drug: EmbryoGlue Medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
Study: NCT05508789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06404333
Drug: CHILD-IVITAB
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 µg/kg) oro-dispersible minitablets
Study: NCT06404333
Drug: CHILD-IVITAB
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400 µg/kg) oro-dispersible minitablets
Study: NCT06498505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT04999969
Drug: AZD0171
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0171
Study: NCT04922398
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline will be injected in each ovary
Study: NCT06199453
Drug: Lutetium (177Lu) vipivotide tetraxetan
Normalized name: lutetium (177Lu) vipivotide tetraxetan
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
Study: NCT06079281
Drug: ALXN1850
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1850 will be administered via subcutaneous (SC) injection.
Study: NCT06079281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via SC injection.
Study: NCT06150898
Drug: Ketorolac 10 Mg Oral Tablet
Normalized name: ketorolac 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
Study: NCT06249945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Study: NCT06484075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be a tablet, but only containing inert inactive ingredients.
Study: NCT06616532
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a predefined dose and date.
Study: NCT05722002
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses
Study: NCT05722002
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
Study: NCT06584071
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM8002 via IV infusion, Q3W
Study: NCT06584071
Drug: PM1009
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM8002 via IV infusion, Q3W
Study: NCT06191978
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06465641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose in capsules
Study: NCT05010954
Drug: LXI-15028 50mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
Study: NCT06053580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 24 weeks.
Study: NCT04989413
Drug: Placebo oral drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of placebo for 12 weeks
Study: NCT06045793
Drug: Placebo (Injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single IV injection of placebo with usual care (UC).
Study: NCT05358717
Drug: PTC518
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC518 will be administered per dose and schedule specified in the arm.
Study: NCT05128773
Drug: Amcenestrant-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT05358717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to PTC518 will be administered per schedule specified in the arm.
Study: NCT06173206
Drug: SP (Macleods Pharmaceuticals Ltd)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
Study: NCT06173206
Drug: SPAQ (Guilin Pharmaceuticals)
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
Study: NCT06501989
Drug: Biweekly 5-FLUOROURACIL (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
Study: NCT06501989
Drug: Biweekly Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
Study: NCT06501989
Drug: Biweekly FOLFIRI
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks.
Study: NCT06501989
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
Study: NCT05507554
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.
Study: NCT05507554
Drug: Non-Opioid Analgesic
Normalized name: Non-opioid analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later.
Study: NCT05849090
Drug: Cephalosporin or clindamycin/vancomycin antibiotics..
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
Study: NCT05849090
Drug: Vancomycin and Tobramycin antibiotics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 gram) and tobramycin (1.2 grams).